NHS 24 is not being piloted in the Grampian region; Grampian is the first part of Scotland to benefit from the national rollout of this new NHS service. NHS 24 was designed and developed with the support of staff from the Scottish Ambulance Service and accident and emergency services to complement these services. By providing callers with home care advice or, where required, directing them to the most appropriate NHS service it should help reduce inappropriate demand on these services. NHS 24 is working very closely with NHSScotland to maximise nursing resource and minimise impact on local NHS services. Consequently, no additional funding was provided to the Grampian NHS Board area solely because NHS 24 would be launched in that area.

The Health Technology Board for Scotland provides timely advice on the clinical and cost effectiveness of the broad range of existing and new health technologies to NHSScotland, including most recently for mental health on:the prescription of anti-cholinesterases to people with Alzheimer's Disease, andthe prescription of atypical anti-psychotics to people with schizophrenia.NHS Scotland and their care partners will also continue to invest in treatments, approaches, services, support and other interventions that aim not only to treat but also to prevent or reduce the incidence and individual severity of mental illness in Scotland. In terms of investment, over £600 million spent last year alone offers a clear signal of the priority we attach to and our national programme to improve mental health and well-being further signals our intent to maintain this profile.

Record sums are being invested in the NHS by the Scottish Executive so that we can revitalise services for patients everywhere. As part of our detailed plans for workforce development, we are working at local, regional and national levels to provide attractive career opportunities for staff at all levels.

In setting the new national maximum waiting time target of six months for a first out-patient appointment, we have taken account of record levels of investment in the NHS which will enable more resources to be deployed to meet growth in demand, for example by increasing numbers of consultants and nurses and making substantial investment in buildings and IT equipment. Moreover, the Centre for Change and Innovation will support and facilitate new and innovative ways of working. The Executive believes that NHS boards and trusts will meet the new target by 2006 and that the people of Scotland will welcome this commitment to reducing out-patient waits.

Stroke medicine is a continuously advancing field. Our Coronary Heart Disease and Stroke Strategy, which we will publish shortly, will set out arrangements designed to make sure that people in Scotland who have had a stroke can benefit at as early a stage as possible from those advances.

The Care Development Group acknowledged that the cost of the policy would be affected by changes in demography and specific account has been taken of this in allocating resources.

Substantial additional resources are being made available to the NHS in Scotland over the years of the spending review as announced on 12 September 2002, with an average annual increase of 8.7% over the years 2003-04 to 2005-06 rising to £8.6 billion a year by the end of the period. Within these substantially increased resources, NHS boards are responsible for ensuring that patients residing in their areas have access to clinically appropriate treatment, including new drug treatments. At Scottish level, the Health Technology Board for Scotland reviews new drug treatments and provides guidance on their use. NHSScotland is expected to take account of advice and evidence from the HTBS and ensure that recommended drugs or treatments are made available to meet clinical need. At local level, Area Drug and Therapeutic Committees are responsible for giving advice to clinicians and for ensuring consistent application of national and local guidelines.

At any time there are a variety of potentially new technologies for the treatment of cancer being researched or undergoing clinical trials throughout the world. These may include novel gene therapy, new equipment or more sophisticated forms of existing equipment, new drugs or other interventions.The Health Technology Board for Scotland is responsible for providing evidence-based advice to NHSScotland on the clinical and cost effectiveness of new and existing health technologies (medicines, devices, clinical procedures and health care settings).

The Spending Review 2002 settlement reflects the Care Development Group's costing assumptions for free personal care. These assumptions estimated an increase in demand from unmet need and a shift from informal to formal care of approximately 12% building up over the first two years of the policy to 2004-05. Within that framework, identification of individuals in need of care is a matter for local authorities. The Scottish Executive has provided the necessary resources.

The Food Standards Agency have advised me that they are committed to reducing food-borne illness in Scotland by at least 20%, by 2006.The funding allocated to reduce food-borne illness across the spending review period is:

2003-04	£1.4 million
2004-05	£4.1 million
2005-06	£3.9 million